Selected Grants
TAK-079-3002
Clinical TrialPrincipal Investigator · Awarded by Takeda Development Center Americas, Inc · 2025 - 2027ARGX-113-2402
Clinical TrialPrincipal Investigator · Awarded by Argenx BV · 2025 - 2027Hematology & Transfusion Medicine (T32)
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 1975 - 2026Prospective Randomized open blinded end-point (PROBE) study
Clinical TrialPrincipal Investigator · Awarded by Baim Institute for Clinical Research · 2018 - 2021Phase IV open label study of Emicizumab Prophylaxis in Hemophila A patients undergoing minor surgery
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2018 - 2020Edoxaban in VTE Associated with Cancer Hokusai VTE Cancer Study DU176b-D-U311
Clinical TrialPrincipal Investigator · Awarded by Daiichi Sankyo Inc · 2015 - 2020An open-label, multicenter, Post-Marketing Requirement study to investigate the safety and tolerability of octaplas in the management of pediatric patients who require therapeutic plasma exchange
Clinical TrialPrincipal Investigator · Awarded by Octapharma AG · 2017 - 2019ART Study (Rituximab as adjunct therapy with plasma exchange in TTP patients)
Clinical TrialPrincipal Investigator · Awarded by Washington University School of Medicine · 2015 - 2019Microfluidic quartz resonator based blood plasma coagulation monitors
ResearchCollaborator · Awarded by Qatch Technologies LLC · 2017 - 2018A Phase III Trial with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura
Clinical TrialPrincipal Investigator · Awarded by Ablynx · 2016 - 2017RE-VERSE-AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial
Clinical TrialPrincipal Investigator · Awarded by Boehringer Ingelheim Pharmaceuticals, Inc. · 2015 - 2017Public Health Surveillance of Bleeding
ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2011 - 2016A randomized, blinded, placebo-controlled, dose finding study to assess the safety and efficacy of the oral thrombopoietin receptor agonist, eltrombopag, administered to subjects with acute myelogenous leukaemia (AML) receiving induction chemotherapy
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2013 - 2016External Relationships
- Novartis Pharmaceuticals
- Sanofi-Aventis
- Takeda Pharmaceutical Co. Ltd.
- argenx US, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.